Abstracts Archive - Page 85 of 2607 - ACR Meeting Abstracts

Abstract Number: 0036 • ACR Convergence 2025
Integrated Analysis of Polygenic and Environmental Risk Scores for Late-Onset Systemic Lupus Erythematosus
Mehmet Hocaoglu¹ and Amr Sawalha², ¹University of Pittsburgh Medical Center, Piitsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Polygenic risk scores (PRS) have been constructed to summarize genetic risk but there is limited research on environment-wide analysis of risk factors for systemic…
Abstract Number: 2278 • ACR Convergence 2025
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
John Tesser¹, Angela Crowley², Jane Box³, Joshua June⁴, Pendleton Wickersham⁵, Guillermo Valenzuela⁶, Norman Gaylis⁷, Gordon Lam⁸, Leroy Pacheco⁹, David Ridley¹⁰, Gineth Pinto-Patarroyo¹¹, Stuart Novack¹², Melvin Churchill¹³, Minna Kohler¹⁴, Eric Lee¹⁵, Jose A Pando¹⁶, Glenn R. Parris¹⁷, Jeff Peterson¹⁸, Tina Shah¹⁹, Atul Singhal²⁰, Victoria Vuong²¹, Jeffrey Curtis²² and David Chernoff²³, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ³DJL Clinical Research, PLLC, Charlotte, NC, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁸Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ⁹Albuquerque Ctr for Rheumatology, Albuquerque, NM, ¹⁰Saint Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Herndon, VA, ¹²Nuvance Health network, NORWALK, CT, ¹³Arthritis Center of Nebraska, Lincoln, NE, ¹⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁵Inland Rheumatology and Osteoporosis Medical Group, Upland, CA, ¹⁶Delaware Arthritis, Lewes, DE, ¹⁷PARRIS & ASSOCIATES, Lilburn, GA, ¹⁸Western Washington Arthritis Clinic, Seattle, WA, ¹⁹Kansas City Physician Partners, Kansas City, MO, ²⁰SouthWest Arthritis Research Group, Mesquite, TX, ²¹Long Island Regional Arthritis & Osteoporosis Care, Hicksville, NY, ²²University of Alabama at Birmingham, Birmingham, AL, ²³SetPoint Medical, Sausalito, CA
Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…
Abstract Number: 0504 • ACR Convergence 2025
Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
Vincent Wong¹, Katie Lowe², Annabelle Small³, Christopher Altmann³, Susanna Proudman⁴, Malcolm Smith², Wittaya Suwakulsiri⁵, Ranjeny Thomas⁵, Chung Hoow Kok⁶ and Mihir Wechalekar⁷, ¹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ²Flinders University, Adelaide, South Australia, Australia, ³Flinders University, Bedford Park, South Australia, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ⁶Centre for Cancer Biology, and Clinical Health Sciences, University of South Australia, Adelaide, South Australia, Australia, ⁷Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Rheumatoid arthritis (RA) shows heterogeneous therapeutic responses that may reflect diversity within synovial tissue (ST). We aimed to identify gene signatures that predict Adalimumab…
Abstract Number: 0490 • ACR Convergence 2025
Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis
Li Liu¹, Xue-Mei Zhang¹, Zhi-Chun Gu¹ and Jia Li², ¹Ren Ji Hospital, Shanghai Jiao Tong University School Of Medicine, Pu Dong Xin Qu, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: This study aimed to evaluate the infection risks in patients with rheumatoid arthritis (RA) treated with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs),…
Abstract Number: 0401 • ACR Convergence 2025
Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Daniel Lovell¹, Nicolino Ruperto², Jennifer Huggins³, Ekaterina Alexeeva⁴, Colleen Correll⁵, John Bohnsack⁶, Stacey Tarvin⁷, Gabriele Simonini⁸, Thomas Griffin⁹, Andrew Zeft¹⁰, Gerd Horneff¹¹, Pierre Quartier¹², Iionka Orban¹³, Heather Walters¹⁴, Valda Stanevica¹⁵, Julisa Patel¹⁶, Adam M Huber¹⁷, Margalit Rosenkranz¹⁸, Daniel Kingsbury¹⁹, Rosie Scuccimarri²⁰, Gabriel Vega Cornejo²¹, Joost Swart²², Robert Carroll²³, Hermine Brunner¹, Tina Sherrard²⁴, Chiara Pallotti²⁵, Clara Malattia²⁶ and Alberto Martini²⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Università degli Studi Milano-Bicocca, Milan, Italy, ³Cincinnati Children's Medical Center, Cincinnati, OH, ⁴National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Utah, Salt Lake City, UT, ⁷Riley Hospital for Children at Indiana University, Indianapolis, IN, ⁸Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ⁹Atrium Health Levine Children’s Hospital, Charlotte, NC, ¹⁰Cleveland Clinic, Cleveland, OH, ¹¹Asklepios Klinik, Hamburg, Germany, ¹²Hôpital Necker-Enfants Malades, Paris, France, ¹³Department of Rheumatology and Clinical Immunology of Semmelweis University, Budapest, Hungary, ¹⁴Northwell, New Hyde Park, NY, ¹⁵Riga Stradiņš University, Riga, Latvia, ¹⁶Children’s Hospital of Georgia, Augusta University, Augusta, GA, ¹⁷IWK Grace Health Centre, Halifax, NS, Canada, ¹⁸University of Pittsburgh, Pittsburgh, PA, ¹⁹Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ²⁰McGill University Health Centre, Montreal, QC, Canada, ²¹Clinica de reumatología Guadalajara, Guadalajara, Jalisco, Mexico, ²²Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ²³Bristol Myers Squibb, London, United Kingdom, ²⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²⁵Istituto G. Gaslini, Servizio di Sperimentazioni Cliniche Pediatriche, Genova, Italy, ²⁶Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients (pts) with JIA have been…
Abstract Number: 0442 • ACR Convergence 2025
Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Charis Meng¹, Marie-France Valois², Caci Julia³, Yvonne Lee⁴, Bindee Kuriya⁵, Gilles Boire⁶, Hugues Allard-Chamard⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Carter Thorne¹¹, Susan J. Bartlett¹², Janet Pope¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Pointe-Claire, QC, Canada, ³Hospital for Special Surgery, New York, ⁴Northwestern University, Chicago, IL, ⁵Mount Sinai Health, Toronto, Canada, ⁶Retired, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Manitoba, Winnepeg, Canada, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²McGill University, Beaconsfield, QC, Canada, ¹³University of Western Ontario, London, ON, Canada
Background/Purpose: A third of patients with early (e)RA report pain outside the joint or non-articular pain (NAP) despite RA treatment(1). NAP, both regional and widespread,…
Abstract Number: 0070 • ACR Convergence 2025
Integrating Synovial Protein Signatures and Serum Profiles to Predict Disease Activity and Treatment Response in Early Rheumatoid Arthritis
Chary López pedrera¹, Sagrario Corrales², Julio Osuna³, Rafaela Ortega-Castro⁴, Jerusalén Calvo⁵, Lourdes Ladehesa⁶, Ismael Sanchez-Pareja², Laura muñoz-Barrera², Desiree Ruiz-Vilchez⁷, Christian Merlo⁸, MARIA ANGELES AGUIRRE ZAMORANO², Nuria Barbarroja⁹, Tomás Cerdó², Marta Alarcon-Riquelme¹⁰, Carlos Pérez Sánchez¹¹, Alejandro Escudero Contreras⁵ and Concepción Aranda-Valera⁵, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Spain., Córdoba, Republic of Korea, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁵IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁶IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁷Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ⁸Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁰Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The analysis of synovial tissue has been instrumental in advancing our understanding of Rheumatoid Arthritis (RA) pathogenesis. As an alternative, the identification of serum…
Abstract Number: 0275 • ACR Convergence 2025
A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study
Stefano Gentileschi¹, Carla Gaggiano¹, Francesco Placido¹, Riccardo Terribili¹, Laura Cometi², Giuseppe Lopalco³, Greta Dipetrangelo³, Giacomo Cozzi⁴, Roberto Padoan⁵, Riccardo Bixio⁶, Simone Parisi⁷, Maria Chiara Ditto⁸, Gemma Lepri⁹, Caludia Fabiani¹⁰, Luca Cantarini¹, Florenzo Iannone¹¹, Roberta Ramonda¹², Bruno Frediani¹ and Serena Guiducci², ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy, ²Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ³Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University o f Bari, Bari, Italy, Bari, Italy, ⁴Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, Padua, Italy, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ⁶Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy, Verona, Italy, ⁷Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁸SC Reumatologia, AOU Città della Salute e della Scienza, Torino, Italy, Turin, Italy, ⁹Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹⁰Ophthalmology Unit, Department of Medical Sciences, Surgery and Neuroscience, University of Siena, Siena University Hospital [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy, Siena, Italy, ¹¹Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹²Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: A new subcutaneous formulation of infliximab (CT-P13) has recently become available for the treatment of inflammatory rheumatic diseases (IRDs), psoriasis and inflammatory bowel diseases.…
Abstract Number: 0496 • ACR Convergence 2025
Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Mitndbaim Parra¹, Rafaela Ortega-Castro², Jerusalén Calvo³, Francisco Jose Cepas⁴, Montserrat Robustillo-Villarino⁵, Andres Zuniga-Vera⁵, Ana Martinez-Feito⁶, Chamaida Plasencia-Rodríguez⁷, Ester Costa-Moya⁸, Delia Taverner-Torrent⁸, Luis Sainz Comas⁹, Cesar Diaz-Torne⁹, Virginia Ruiz-Esquide¹⁰, Cynthia Rojas¹¹, Lourdes Martin-de la Sierra Lopez¹², Laura Jimenez-Rodriguez¹², David Velasco-Sanchez¹², Regina Fará Garcia¹³, Antonio Juan-Mas¹⁴, Marina soledad Moreno Garcia¹⁵, Ana Valeria Acosta Alfaro¹⁶, Santiago Muñoz¹⁷, Maria Martín López¹⁸, Raquel Zas¹⁹, FRANCISCO JAVIER GODOY NAVARRETE²⁰, Isabel Anon Onate²¹, Fernando Ortiz-Márquez²², Natalia Mena Vázquez²³, Paula Estrada-Alarcón²⁴, Lourdes Ladehesa²⁵, Alejandro Escudero Contreras³ and Clementina López Medina²⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁶Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁷Hospital Universitario La Paz, MADRID, Spain, ⁸Hospital Sant Joan Reus, Reus, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹¹Hospital Clinic, Barcelona, Spain, ¹²Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹³Hospital Son Llàtzer, Palma, Spain, ¹⁴Son Llazter University Hospital, Madrid, Spain, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁶Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁷Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁸Hospital ¹² de Octubre, Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Jaen University Hospital, Spain, Jaen, Spain, ²¹Hospital Universitario de Jaén, Jaén, Spain, ²²Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²⁴Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody directed against the Fc fragment of IgG that plays a key role in the development of rheumatoid arthritis…
Abstract Number: 0514 • ACR Convergence 2025
Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Nicholas Bauer¹, Rufei Lu¹, Carla Guthridge¹, Tayte Stephens², Benjamin Jones³, Wade DeJager⁴, Susan Macwana¹, Caroline Shiboski⁵, Alan Baer⁶, Christopher Lessard¹, Astrid Rasmussen¹, Stephen Shiboski⁵, Judith James¹, Linda F. Thompson¹, Blake M. Warner⁷, A. Darise Farris¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma State University, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵University of California San Francisco, San Francisco, CA, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷National Institutes of Health, Bethesda, MD
Background/Purpose: Blood immunophenotyping reveals systemic immune alterations and therapeutically actionable molecular endotypes in Sjögren’s Disease (SjD). Reported changes include reduced memory B cells, plasmacytoid dendritic…
Abstract Number: 0452 • ACR Convergence 2025
Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments
Keigo Hayashi¹, Kei Hirose², Natsuki Kubota¹, Yuya Terajima¹, Kazuya Matsumoto¹, Takato Nakadoi¹, Shoichi Nawachi¹, Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama¹, Haruki Watanabe¹, Mariko Narazaki¹, Yoshinori Matsumoto¹ and Jun Wada¹, ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) and osteoporosis management that have improved patient outcomes, osteoporosis continues to be a significant clinical concern in RA.…
Abstract Number: 0292 • ACR Convergence 2025
Patterns and Predictors of Longitudinal Trajectories of Pain in Individuals with Inflammatory Myopathies
Haley Zimmerman¹, Ethan Ritz², Kristin Wipfler³, Kaleb Michaud⁴ and Didem Saygin¹, ¹Rush University Medical Center, Chicago, IL, ²Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Idiopathic inflammatory myopathies (IIM) have historically been considered a disease of painless weakness. However, recent studies indicate that most patients with IIM experience pain…
Abstract Number: 0528 • ACR Convergence 2025
Apolipoprotein A1 and B Levels Indicate Specific Lipid Changes In Early Treatment Naïve Psoriatic Arthritis and Correlate With 1-year Disease Activity
Alla Ishchenko¹, Margot Van Mechelen², Barbara Neerinkx¹, Patrick Verschueren³, Rik Lories¹ and Kurt de Vlam⁴, ¹KU Leuven, Leuven, Belgium, ²UZA Antwerp, Antwerp, Belgium, ³Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁴KU Leuven, UZ Gasthuisberg, Leuven, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is associated with increased cardiovascular risk and a pro-atherogenic lipid profile. We hypothesize that alterations in lipid metabolism combined with systemic…
Abstract Number: 0431 • ACR Convergence 2025
Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
Sangeeta Kumari¹, Eric meldrum¹, Josephine Stein¹, Tirza Bruurmijn¹, Robin de Jong², Katerina Pardali¹, Maarten Kraan¹, Renato Chirivi¹, Rogier Thurlings³ and Michael Nurmohamed², ¹Citryll BV, Oss, Netherlands, ²Reade, Amsterdam, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: Calprotectin is a protein highly expressed in myeloid cells and its elevated presence in blood, and the GI tract is associated with immune mediated…
Abstract Number: 0509 • ACR Convergence 2025
Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
Martha Tsaliki¹, Joshua Cavett², Biji T Kurien³, valerie Lewis³, John Ice⁴, Devavrat Dave⁵, Sina Khosravani⁵, Menerva Racy⁵, Rebecca Wood⁶, Seunghee Cha⁷, A. Darise Farris³, Kristi A. Koelsch⁵ and R. Scofield³, ¹The University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medicar Research Foundtion, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴OKC Veterans Affairs Medical Center, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, oklahoma City, ⁶University of Oklahoma Health Sciences Center, Edmond, OK, ⁷University of Florida, Gainesville
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease characterized by immune-mediated damage to salivary and lacrimal glands. While autoantibodies against muscarinic type 3 receptor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].